Ryanodine receptor 2 inhibitor

This page covers all Ryanodine receptor 2 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting RyR2.

Targets

RyR2

Phase 2 pipeline (1)

• GSK256066 · GlaxoSmithKline · Cardiovascular
  GSK256066 is a selective and potent inhibitor of the cardiac ryanodine receptor 2.

Patent intelligence

• ryanodine receptor 2 inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates